Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 17/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321266 | 1.00 | ROCK2 (1.00) | ROCK2KDM4ENPC1CYP1A2CYP2D6 | |
| SCHEMBL10069813 | 0.91 | ROCK2 (0.83) | ROCK2KDM4ENPC1CYP1A2CYP2D6 | |
| SCHEMBL10311368 | 0.91 | ROCK2 (0.83) | ROCK2KDM4ENPC1CYP1A2CYP2D6 | |
| SCHEMBL10277530 | 0.88 | ROCK2 (0.78) | ROCK2KDM4ENPC1CYP1A2CYP2D6 | |
| SCHEMBL10069994 | 0.86 | ROCK2 (1.00) | ROCK2KDM4ENPC1CYP1A2CYP2D6 | |
| SCHEMBL321267 | 0.85 | ROCK2 (0.86) | ROCK2KDM4ENPC1CYP1A2CYP2D6 | |
| SCHEMBL10070022 | 0.84 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL10070028 | 0.84 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL10070019 | 0.82 | ROCK2 (1.00) | ROCK2KDM4ENPC1CYP1A2CYP2D6 | |
| SCHEMBL308394 | 0.81 | ROCK2 (0.73) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590942-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-04 | — | — | EP | disclosed |
| EP-2590942-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-04 | — | — | EP | disclosed |
| US-9079880-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-9079880-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-9079880-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| EP-2590942-A1 | RHO KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-20120178752-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
| US-20120178752-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
| US-20120178752-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
| WO-2012006202-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178752-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | ROCK2 2/4885KDM4E 1831/4885NPC1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.